Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Randomized Controlled Clinical Trial Evaluating the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) as Adjunct to Standard of Care (SOC) Therapy Compared to SOC Alone in the Management of Diabetic Foot Ulcers

NCT07116174 is registered in ClinicalTrials.gov with New Horizon Medical Solutions as lead sponsor.

NCT NCT07116174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07116174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Randomized Controlled Clinical Trial Evaluating the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) as Adjunct to Standard of Care (SOC) Therapy Compared to SOC Alone in the Management of Diabetic Foot Ulcers
Lead sponsor
New Horizon Medical Solutions
Phase
Not applicable
Overall status
Recruiting
Start date
August 15, 2025
Completion date
August 15, 2026
Enrollment
135 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer (dfu)